Dec 31, 2019

Bausch Health Q4 2019 Earnings Report

Bausch Health reported revenue growth and adjusted EBITDA increase, driven by Salix and Bausch + Lomb/International segments.

Key Takeaways

Bausch Health Companies Inc. announced its fourth-quarter and full-year 2019 financial results, demonstrating consistency and durability with revenue growth and strong performance in the Salix and Bausch + Lomb/International segments. The company delivered total company reported revenue growth of 5% in the fourth quarter and 3% for the full year of 2019.

Revenues of $2.224 Billion

GAAP Cash Generated from Operations of $234 Million

GAAP Net Loss of $1.516 Billion

Adjusted EBITDA (non-GAAP) of $898 Million

Total Revenue
$2.22B
Previous year: $2.12B
+4.9%
EPS
$1.12
Previous year: $1.05
+6.7%
Adjusted EBITDA
$898M
Cash from Operations
$234M
Gross Profit
$1.59B
Previous year: $1.52B
+4.6%
Cash and Equivalents
$3.24B
Previous year: $721M
+349.9%
Free Cash Flow
$156M
Previous year: $257M
-39.3%
Total Assets
$33.9B
Previous year: $32.5B
+4.2%

Bausch Health

Bausch Health

Bausch Health Revenue by Segment

Forward Guidance

Bausch Health provided guidance for the full year of 2020, as follows: • Full-Year revenues in the range of $8.65 - $8.85 billion • Full-Year Adjusted EBITDA (non-GAAP) in the range of $3.50 - $3.65 billion

Revenue & Expenses

Visualization of income flow from segment revenue to net income